Gain Therapeutics (GANX) news
Recent news
Gain Therapeutics Q2 EPS USD -0.11
Gain Therapeutics, Inc. (Nasdaq: GANX) reported a net loss per share of $-0.11 for the second quarter of 2026, based on recent estimates and financial trends . This figure reflects the company’s ongoing investment in clinical development and research activities, particularly for its lead drug…
AInvest Wire · Aug 11, 2026Corrected-Gain Therapeutics - FDA decision allows initiation of Phase 2 for GT-02287 (not 'GT-2287') in Parkinson's disease
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced that it is on track to initiate a Phase 2 clinical trial for its lead drug candidate, GT-02287, in the treatment of Parkinson’s disease following the submission of additional preclinical data requested by the U.S. Food and Drug Administration…
AInvest Wire · Jun 29, 2026Corrected-Gain Therapeutics - GT-02287 (not 'GT-2287') phase 2 clinical development in U.S. expected to initiate during 3Q26
AInvest Wire · Jun 29, 2026Gain Therapeutics receives FDA clearance of IND to advance GT-02287 into Phase 2 clinical development for Parkinson’s disease
AInvest Wire · Jun 29, 2026Gain Therapeutics - GT-2287 Phase 2 clinical development in U.S. expected to initiate during 3Q26
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.